BACKGROUND: We previously reported decreased transfusions and donor exposures in preterm infants randomized to Darbepoetin (Darbe) or erythropoietin (Epo) compared with placebo. As these erythropoiesis-stimulating agents (ESAs) have shown promise as neuroprotective agents, we hypothesized improved neurodevelopmental outcomes at 18 to 22 months among infants randomized to receive ESAs. METHODS: We performed a randomized, masked, multicenter study comparing Darbe (10 μg/kg, 1×/week subcutaneously), Epo (400 U/kg, 3×/week subcutaneously), and placebo (sham dosing 3×/week) given through 35 weeks' postconceptual age, with transfusions administered according to a standardized protocol. Surviving infants were evaluated at 18 to 22 months' corrected age using the Bayley Scales of Infant Development III. The primary outcome was composite cognitive score. Assessments of object permanence, anthropometrics, cerebral palsy, vision, and hearing were performed. RESULTS:Of the original 102 infants (946 ± 196 g, 27.7 ± 1.8 weeks' gestation), 80 (29 Epo, 27 Darbe, 24 placebo) returned for follow-up. The 3 groups were comparable for age at testing, birth weight, and gestational age. After adjustment for gender, analysis of covariance revealed significantly higher cognitive scores among Darbe (96.2 ± 7.3; mean ± SD) and Epo recipients (97.9 ± 14.3) compared with placebo recipients (88.7 ± 13.5; P = .01 vs ESA recipients) as was object permanence (P = .05). No ESA recipients had cerebral palsy, compared with 5 in the placebo group (P < .001). No differences among groups were found in visual or hearing impairment. CONCLUSIONS: Infants randomized to receive ESAs had better cognitive outcomes, compared with placebo recipients, at 18 to 22 months. Darbe and Epo may prove beneficial in improving long-term cognitive outcomes of preterm infants.
RCT Entities:
BACKGROUND: We previously reported decreased transfusions and donor exposures in preterm infants randomized to Darbepoetin (Darbe) or erythropoietin (Epo) compared with placebo. As these erythropoiesis-stimulating agents (ESAs) have shown promise as neuroprotective agents, we hypothesized improved neurodevelopmental outcomes at 18 to 22 months among infants randomized to receive ESAs. METHODS: We performed a randomized, masked, multicenter study comparing Darbe (10 μg/kg, 1×/week subcutaneously), Epo (400 U/kg, 3×/week subcutaneously), and placebo (sham dosing 3×/week) given through 35 weeks' postconceptual age, with transfusions administered according to a standardized protocol. Surviving infants were evaluated at 18 to 22 months' corrected age using the Bayley Scales of Infant Development III. The primary outcome was composite cognitive score. Assessments of object permanence, anthropometrics, cerebral palsy, vision, and hearing were performed. RESULTS: Of the original 102 infants (946 ± 196 g, 27.7 ± 1.8 weeks' gestation), 80 (29 Epo, 27 Darbe, 24 placebo) returned for follow-up. The 3 groups were comparable for age at testing, birth weight, and gestational age. After adjustment for gender, analysis of covariance revealed significantly higher cognitive scores among Darbe (96.2 ± 7.3; mean ± SD) and Epo recipients (97.9 ± 14.3) compared with placebo recipients (88.7 ± 13.5; P = .01 vs ESA recipients) as was object permanence (P = .05). No ESA recipients had cerebral palsy, compared with 5 in the placebo group (P < .001). No differences among groups were found in visual or hearing impairment. CONCLUSIONS:Infants randomized to receive ESAs had better cognitive outcomes, compared with placebo recipients, at 18 to 22 months. Darbe and Epo may prove beneficial in improving long-term cognitive outcomes of preterm infants.
Authors: Cornelieke Sandrine Hanan Aarnoudse-Moens; Jaap Oosterlaan; Hugo Joseph Duivenvoorden; Johannes Bernard van Goudoever; Nynke Weisglas-Kuperus Journal: J Pediatr Date: 2010-08-13 Impact factor: 4.406
Authors: Masanori Iwai; R Anne Stetler; Juan Xing; Xiaoming Hu; Yanqin Gao; Wenting Zhang; Jun Chen; Guodong Cao Journal: Stroke Date: 2010-04-01 Impact factor: 7.914
Authors: Peg C Nopoulos; Amy L Conrad; Edward F Bell; Ronald G Strauss; John A Widness; Vincent A Magnotta; M Bridget Zimmerman; Michael K Georgieff; Scott D Lindgren; Lynn C Richman Journal: Arch Pediatr Adolesc Med Date: 2011-01-03
Authors: Li Zhang; Michael Chopp; Rui Lan Zhang; Lei Wang; Jing Zhang; Ying Wang; Yier Toh; Manoranjan Santra; Mei Lu; Zheng Gang Zhang Journal: PLoS One Date: 2010-06-11 Impact factor: 3.240
Authors: Robin K Whyte; Haresh Kirpalani; Elizabeth V Asztalos; Chad Andersen; Morris Blajchman; Nancy Heddle; Meena LaCorte; Charlene M T Robertson; Maxine C Clarke; Michael J Vincer; Lex W Doyle; Robin S Roberts Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Sandra E Juul; Richard P Beyer; Theo K Bammler; Ronald J McPherson; Jasmine Wilkerson; Federico M Farin Journal: Pediatr Res Date: 2009-05 Impact factor: 3.756
Authors: Robin K Ohls; Daniel C Cannon; John Phillips; Arvind Caprihan; Shrena Patel; Sarah Winter; Michael Steffen; Ronald A Yeo; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe Journal: Pediatrics Date: 2016-02-15 Impact factor: 7.124
Authors: Mariana C Baserga; Joanna C Beachy; Jessica K Roberts; Robert M Ward; Robert J DiGeronimo; William F Walsh; Robin K Ohls; Jennifer Anderson; Dennis E Mayock; Sandra E Juul; Robert D Christensen; Manndi C Loertscher; Chris Stockmann; Catherine M T Sherwin; Michael G Spigarelli; Bradley A Yoder Journal: Pediatr Res Date: 2015-05-21 Impact factor: 3.756
Authors: E Henry; R D Christensen; M J Sheffield; L D Eggert; P D Carroll; S D Minton; D K Lambert; S J Ilstrup Journal: J Perinatol Date: 2014-09-25 Impact factor: 2.521